Cowlpane has published 11 articles on biotech — primarily in Markets, Economy, Tech , with coverage from 2026. Sourced from global financial publications.
A $5.5 billion blow to short sellers marks a violent reversal for Moderna as cancer vaccine data shifts the biotech narrative.
Moderna's experimental mRNA success shifts the biotech landscape from broad treatments to highly targeted cancer therapies.
Small-cap firms bioAffinity and Algo Grande are tapping private capital to fund critical expansion, shifting their risk-reward profiles for retail investors.
A top biotech exec sells millions of shares, sparking a sector‑wide reassessment of growth prospects
AstraZeneca's potential takeover of Bristol Myers Squibb could create a $400B pharmaceutical titan, reshaping the global drug market landscape.
Moderna abandons its reliance on pandemic-driven revenue to pursue a high-stakes oncology pipeline that has already sent shares up 177%.
Major pharmaceutical giants accelerate biotech acquisitions to replace expiring revenue streams and stave off long-term growth erosion.
Sonja Optendrenk navigates a high-stakes pricing war with US pharma giants that dictates medical access for 74 million people.
Moderna and Merck's personalized mRNA melanoma vaccine proves efficacy in Phase 3 trials, threatening the dominance of traditional oncology regimens.
Researchers apply photosynthetic processes to treat dry eye, potentially disrupting the multi-billion dollar ophthalmic drug market.
New executive orders threaten established vaccine protocols, forcing biotech firms to pivot R&D spending toward politically favored alternatives.